The case for & against
Bull & Bear analysis
Bullish
GoodRx Holdings, Inc. (NASDAQ:GDRX) operates a healthcare platform that facilitates consumer access to prescription drugs by providing pricing information, discounts, and subscription services. The company has established a strong foothold within the pharmaceutical ecosystem, focusing on improving affordability and transparency for consumers navigating a complex healthcare landscape. Its growth strategy centers on expanding its PharmaDirect revenue model and subscription-based services, aiming to address rising healthcare costs and changing consumer behaviors.
Bull says
- ↑Q2 revenue grew 39% YoY to $200.4M with a 31.8% adjusted EBITDA margin
- ↑PharmaDirect revenue jumped 76% YoY to $61.6M across 135+ consumer programs
- ↑Subscription revenue climbed 39% YoY to $28.5M as GoodRx Companion leads
- ↑Full-year guidance raised to $790–$805M, reflecting management confidence
- ↑Positioned to capture rapid GLP-1 demand via deepening manufacturer partnerships
- ↑Valuation supported by high earnings yield and book-to-price; leverage manageable; institutional backing strong
Bear says
- ↓Insider sales of $4.5M may indicate internal confidence issues
- ↓Monthly active consumers declined 12% YoY to 5M, highlighting retention challenges
- ↓Analysts warn of overvaluation risk amid subscription pivot and earnings outlook
- ↓Legacy prescription transaction revenues could fall if subscribers underperform
- ↓Rising healthcare costs and unpredictable coverage may pressure demand
- ↓High stock volatility and weak size and quality metrics deter cautious investors
Investment themes with GDRX
Recent IPOs↓ -2.25%
Companies that recently went public
SNOW · PLTR · PTON
Buybacks↓ -0.29%
Companies repurchasing their own shares
C · JCI · WFC
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 05-09-2025neutral
Transcript signals
Bull points
- During Q1, we continued to sign direct contracts with new pharmacies and expand the drugs covered by direct contracts. In Q1 2023, approximately 5% of our claims were through retail direct contracts and in Q1 2024 they made up over 20% of our clients.
- Q1 year-over-year adjusted revenue growth accelerated to 8%, up compared to our Q4 growth rate and our Q1 adjusted EBITDA margin was 31.7%, up 280 basis points year-over-year with adjusted EBITDA growing 18% year-over-year.
- We anticipate adjusted revenue to be between $800 million and $810 million for the full year 2024, with adjusted EBITDA of over $250 million. We believe we're gaining momentum from a top line and adjusted EBITDA standpoint.
Bear points
- There was an outage. We got our own service back up, but obviously, I think Change has lasted longer than anybody else in the industry would have thought throughout the quarter, and so there were persistent effects that are really centered more around Q2, both around the system and the industry in general.
- There was an outage. We got our own service back up, but obviously, I think Change has lasted longer than anybody else in the industry would have thought throughout the quarter, and so there were persistent effects that are really centered more around Q2, both around the system and the industry in general.
- These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors.
Read full transcript analysis ›